Company News

bioMérieux recently launched IDEA™ STEC, an advanced Immuno Detection Evolution Agar designed to simplify and enhance the confirmation step in the detection of Shigatoxin-producing E. Coli.

In the relentless pursuit of healthcare efficiency and better patient care, one truth is becoming increasingly clear: diagnostics are not just clinical tools—they are economic engines.

bioMérieux has just acquired a stake in Allergen Alert, an innovative startup specializing in the rapid detection of food allergens for individuals and professionals.

bioMérieux confirms its ethical commitment to clinical research through a Bioethics Charter that guarantees transparency, accountability, and respect for human dignity. In particular, it aims to protect research participants when collecting and using biological samples and personal data.

bioMérieux has a long history of collaboration with Moderna, a biotechnology company that gained worldwide recognition during the COVID-19 pandemic for its rapid development of a mRNA-based vaccine. Today, this partnership is helping accelerate the development of individualized cancer treatments.